Operating profit before amortization: Design Therapeutics Inc (DSGN)
The development of Design Therapeutics (DSGN) relies on confirming the efficacy of gene technologies and seeking partners. The company is currently revising its small molecule testing program to verify safety. Total operating profit before depreciation and amortization clearly demonstrates financial stability, where the 0.00 mark serves as a current indicator. This approach has solidified the issuer's status as an innovator creating advanced treatments for rare genetic pathologies.
%20Operating%20profit%20before%20deduction%20of%20amortization&width=1200&height=400&colorIndex=0&v=mwa76aez.ocr-7cpmfb4&start=20220704&end=20261110&filename=GURU_Markets_-_DSGN_-_Design-Therapeutics_-_Operating-profit-before-deduction-of-amortization "DSGN (Design Corp) Income before deduction of interest, taxes and amortization history from 11/23/2025 to 11/10/2026 | 👁️GURU.Markets👁️")
Design Therapeutics, Inc. (DSGN) - metric breakdowns and financial figures
- price and consensus price forecast:
- company stock exchange capitalization indicators:
- balance sheet net asset value indicators:
- company total debt and liquidity indicators:
All Debt to Shareholders' Equity Ratio Design Therapeutics|DSGN - Long-Term Debt to Capital|Current Liabilities to Capital Design Therapeutics Inc|DSGN - Company Debts|Debt to Net Assets Ratio Design Therapeutics|DSGN - Company Long-Term Debts|Company Short-Term Debts Design Therapeutics|Critical Liquidity Ratio designtx.com
- earnings and market ratios statistics:
DSGN - Net Profit|Expected Net Profit Design Therapeutics|DSGN - Price to Earnings Ratio|Forward P/E Multiple designtx.com|DSGN - Price/Earnings to Growth Multiple|Enterprise Value to Operating Income Before Depreciation Ratio Design Therapeutics|DSGN - Operating profit EBITDA|Net earnings per share for the last four quarters Design Therapeutics|DSGN - Net earnings per share (EPS TTM)|Year-over-year net earnings per share growth for the last 12 months designtx.com|DSGN - Earnings per share growth in current year|Consensus forecast of earnings per share growth for next year Design Therapeutics
Analysis of all company metrics:Design Corp
This metric measures net cash flow from operating activities before taxes and interest, allowing investors to instantly diagnose revenue disruptions and cost management efficiency. By analyzing the cash EBITDA, one can assess the financial stability of Design Therapeutics (DSGN) as it develops safe small molecules to correct genetic defects without direct intervention in the DNA structure.
Who Design Therapeutics competes with
Operating profit before depreciation charges Tempus|QGEN - Profit before payment of interest, taxes and amortization|IONS (ionispharma.com) - Operating profit before amortization|RGEN (Repligen) - Operating profit before deduction of amortization|Avidity Biosciences Inc - Income before deduction of interest, taxes and amortization|Operating profit before deduction of amortization CRSP|WGS (GeneDx Corp) - Company profit before taxes, interest and amortization|Operating profit EBITDA RARE|BEAM (beamtx.com) - Income before deduction of interest, taxes and amortization|Operating profit EBITDA SRPT (Sarepta)|Twist Bioscience Inc (TWST) - Profit before interest, taxes and amortization|TXG - Profit before payment of interest, taxes and amortization|Income before deduction of interest, taxes and amortization NTLA (Intellia Corp)|STOK: Operating profit EBITDA|biolifesolutions.com (BLFS) - Operating profit EBITDA|Profit before payment of interest, taxes and amortization Wave Life Sciences Ltd.|Maze Therapeutics, Inc. - Profit before deduction of interest, taxes, depreciation and amortization|Operating profit EBITDA SION|PRME - Profit before interest, taxes and amortization|Taysha Gene Therapies - Operating profit before deduction of amortization|Operating profit EBITDA uniqure.com QURE|MGTX: Operating profit before deduction of amortization|REGENXBIO Inc - Company profit before taxes, interest and amortization|SLDB: Operating profit EBITDA|OCGN - Operating income before deduction of amortization|PACB (Pacific Biosciences) - Operating profit EBITDA|Operating profit before deduction of amortization benitec.com (BNTC)|Profit before payment of interest, taxes and amortization Rocket Pharmaceuticals, Inc. (RCKT)|Operating income before deduction of amortization 4DMT|Operating profit EBITDA LXEO (Lexeo Therapeutics, Inc.)|KRRO: Operating profit before amortization|EDIT - Profit before payment of interest, taxes and amortization|Operating income before deduction of amortization silence-therapeutics.com SLN|PRQR: Operating profit EBITDA|Operating profit before depreciation charges Codexis CDXS|Profit before payment of interest, taxes and amortization Sangamo|Operating profit before amortization NAUT (Nautilus Biotechnology Inc)|Operating profit EBITDA MGX|precisionbiosciences.com - Operating profit before amortization|Profit before payment of interest, taxes and amortization Generation Bio GBIO|BOLD: Operating profit before amortization|Exicure Corp - Operating profit EBITDA|IMNN - Operating profit EBITDA|PHIO: Operating profit EBITDA|Operating profit before amortization MBIO|RNAZ (TransCode Therapeutics Inc.) - Operating profit EBITDA|Profit before interest, taxes and amortization Bionano BNGO|Profit before payment of interest, taxes and amortization Applied DNA (APDN)|Operating income before deduction of amortization bluebird bio, Inc|Operating profit EBITDA IPA (ImmunoPrecise Antibodies Ltd.)|Operating income before deduction of amortization omegatherapeutics.com (OMGA)|Singular Genomics - Operating profit EBITDA|Operating profit before depreciation charges Regulus Therapeutics, Inc. (RGLS)|Syros (SYRS) - Profit before payment of interest, taxes and amortization|Operating profit before amortization TBIO|Operating profit before deduction of amortization TCON|UBX: Income before deduction of interest, taxes and amortization
